An observational study in Aged 60 Years or Older, sponsored by European University Miguel de Cervantes. Recruiting at 2 sites in Spain. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by European University Miguel de Cervantes · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies in Frailty with a site in Spain — 46 open to participants now, 54 under way, none of them phase 3. Frailty · Spain.
Among the 132 studies in Frailty with a site in Spain, this one is the 32nd largest by planned enrollment of the 36 observational ones that give a count, is one of 16 that started in 2025, is one of 36 observational ones, reaches primary completion later than 49 of the 53 other live ones, and was the 89th registered.
1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.
Browse Frailty studies →46 of the 132 studies in Frailty with a site in Spain are open now. Recruiting first, the newest first:
Universidad de Granada · Sites in Spain
Ages 65+
University of Vigo · Sites in Spain
Ages 70+
Fundacion Miguel Servet · Sites in Spain
Ages 75+
Alberto Bermejo Franco · Sites in Spain
Ages 70+
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 65+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 16 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 82 is below the median of 225 across 495 observational studies indexed under Frailty.
Median enrollment 90 across the 96 interventional studies, 432 across the 36 observational. Of the 60 that completed or were terminated, 2 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 132 have an industry lead sponsor. The 10 most frequent:
European University Miguel de Cervantes is the lead sponsor of 16 studies on the registry; 9 are open to participants now.
European University Miguel de Cervantes has 2 studies filed under Frailty — fewer than ten, so there is no comparison to draw.
11 of the studies in Frailty with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04926597Philipp SchuetzEffect of Continued Nutritional Support at Hospital Discharge on Mortality, Frailty, Functional Outcomes and Recovery | 2026-12 |
| NCT06556537Universidad de ZaragozaEffects of Physical Exercise on Frailty, Mental and Physical Health of Older Adults in Rural Areas. | 2026-12-20 |
| NCT07275996Universidad de BurgosNeuromuscular and Multi-Omics Synergy of Combined Creatine × HMB Supplementation Plus Exercise to Improve Muscle Function in Sarcopenic Frailty | 2026-12-30 |
| NCT07643064Alberto Bermejo FrancoMulticomponent Exercise and Comprehensive Geriatric Assessment Program (FRAIL+AP) for Frail Older Adults in Primary Care | 2026-12-31 |
| NCT07848802University of VigoPhysical Function and Fall Risk in Older Adults in the Lalín Frailty Prevention Program | 2027-01-15 |
Add all 11 to your calendar (.ics) → With an account.
Among the 132 studies in Frailty with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aging is a biological process that is accompanied by a progressive deterioration of physical and mental abilities and leads to an increased risk of disease. In 2023, Spain will reach an all-time high aging rate of 137.7% due to the low birth rate and increasing life expectancy. In Castilla y León, 47.57% of the population lives in municipalities with fewer than 20,000 inhabitants. This percentage has decreased over the last 10 years, reflecting a clear trend towards rural exodus, and this population loss requires the development of specific measures. Spanish Law 45/2007 includes as one of its objectives the promotion of quality social services and the guarantee of access to public services for older adults. However, geographical dispersion limits the effective implementation of these services. Although Castilla y León has a good network of local clinics, medical care in many municipalities is outpatient and limited to a weekly consultation. This low frequency of face-to-face care hinders the early detection of diseases, leads to a greater number of avoidable hospitalizations and contributes to older adults isolation. Faced with this reality, the VIVIR (Integrated Monitoring for Independent Living in Rural Settings) project proposes the implementation of an innovative system for the continuous monitoring of the health status of the elderly through an advanced comprehensive assessment kit. This kit will include instruments such as electrocardiogram, blood pressure measurement, manual grip strength, assessment of physical and emotional functions, spirometry, body composition and nutritional assessment.
Advances in disease prevention and treatment as well as social changes have led to an increase in life expectancy of around 10-20 years in various regions of the world since the 1950s. However, population growth and aging have led to a sharp increase in the number of older people with physical disabilities, i.e. with difficulties in performing activities of daily living. Aging is defined as a biological process characterized by an increasing accumulation of cellular and molecular damage that leads to a decrease in physical and mental abilities and thus to an increased risk of disease. Currently, more than half of the population in the European Union is 65 years old or older. Furthermore, projections for 2050 indicate a decrease in the ratio of working-age people to older people, reflecting the increasing aging of the European population. In 2023, Spain will reach the historical peak of aging with 137.7% of the population. These demographic changes are also expected to increase the number of age-related diseases and conditions, including frailty. Frailty can be defined as a syndrome caused by the combined effect of multiple age-related and associated changes. Specifically, phenotypic frailty is a validated clinical presentation that marks a distinct clinical syndrome and pathophysiology. Furthermore, the 'Frailty Index' calculates the percentage of clinically identified conditions or impairments in relation to the number of measured diseases, symptoms, signs, impairments, disabilities and functional limitations, social environment, physical activity, mental health, cognitive status, self-assessed health and, in some cases, laboratory findings. A preventive assessment together with the implementation of a care and follow-up plan can have benefits for the well-being and independence of older adults, including reduced hospital admissions, falls and long-term mortality.
Older adults (≥60 years old) with or without chronic diseases living in rural areas of Valladolid
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A single cohort of older adults (≥60 years old) will be used to evaluate the ability of a specific kit to assess the health status and predict adverse events
Other: Devices: Kardia Mobile 6L; Omron M7 BP ; Beurer PO30; Datospir Peak-10; NUTRILAB BIA 101 BIVA® PRO; JAMAR® Smart.
Use of the Kardia Mobile 6L portable device to assess electrocardiogram; Omron M7 BP for blood pressure; Beurer PO30 for oxygen saturation; Datospir Peak-10 for peak flow; NUTRILAB BIA 101 BIVA® PRO for body composition; questionnaires for the nutritional status (Mini-Nutritional Assessment, Malnutrition Universal Screening Tool), JAMAR® Smart for handgrip strength; The Short Physical Performance Battery for frailty status and fall risk; the Geriatric Depression Scale to evaluate depression status; the Fried's frailty phenotype to assess the frailty status; the International Physical Activity Questionnaire for the physical activity levels; SARC-F to identify older adults at risk of sarcopenia; and the Timed-Up and Go for mobility, walking ability and fall risk.
Electrocardiogram (ECG)
A 6-lead ECG will be performed using the Kardia Mobile 6L portable device (AliveCor Inc., California, USA), which is FDA approved and used in clinical practice. This device connects to an application on the phone via Bluetooth to provide instantaneous readings. To perform the measurement correctly, users are asked to sit and rest for 5 minutes. Afterwards, the user should hold the device so that the thumbs touch the upper electrodes, and the device is in direct contact with the skin of the left leg at the knee or ankle. The device gives a diagnosis about heart beat rhythm (e.g., normal sinoauricular rhythm, arritmia, etc.)
Time frame: Visits 1 (Month 1), 2 (Month 2), 3 (Month 3), 4 (Month 7), 5 (Month 19) and 6 (Month 31)
Blood pressure
An Omron M7 automatic blood pressure monitor (Omron Healthcare Co., Ltd., Kyoto, Japan) will be used to measure blood pressure. According to the recommendations of the American Heart Association, the user should sit in a comfortable chair with lumbar support for at least 5 minutes before the measurement. The participant will be asked to place both feet flat on the floor without crossing the legs and place the arm with the cuff at chest level on a table with the palm facing up. Make sure that the cuff is properly adjusted, but not too tight and touching bare skin, before starting the blood pressure measurement. The person being tested should not speak during this procedure to ensure an accurate and reliable measurement. An initial measurement will be taken on each arm to determine the arm with the highest blood pressure. Three measurements will be then taken at least one minute apart. The unit measure is: Millimetre of mercury (mmHg)
Time frame: Visits 1 (Month 1), 2 (Month 2), 3 (Month 3), 4 (Month 7), 5 (Month 19) and 6 (Month 31)
Oxygen saturation
A Beurer PO30 pulse oximeter (Beurer GmbH, Mittelstand, Germany) will be used and placed on the index or middle finger previously cleaned with alcohol. Participants are asked not to apply nail polish to their fingernails. Measurement results will be given in percentage of oxygen saturation (%SatO2)
Time frame: Visits 1 (Month 1), 2 (Month 2), 3 (Month 3), 4 (Month 7), 5 (Month 19) and 6 (Month 31)
Spirometry
An expiratory flow meter (Datospir Peak-10, Sibelmed S.A.U, Barcelona, Spain) will be used to measure peak expiratory flow. The maneuver is performed in a seated position with both feet resting on the floor, the head in a neutral position and a nose clip is used. The participant will be instructed to perform a maximal inhalation followed by a rapid exhalation, with an expiratory effort of 1 to 2 seconds. The patient will be instructed not to cough during the technique and not to flex and/or extend the cervical spine. Three maneuvers will be performed, with the highest value being used for the analysis. Measurement will be given in liter per minute (l/min).
Time frame: Visits 1 (Month 1), 2 (Month 2), 3 (Month 3), 4 (Month 7), 5 (Month 19) and 6 (Month 31)
Bioimpedance
The NUTRILAB BIA 101 BIVA® PRO bioimpedance device (AKERN Srl, Florence, Italy) will be used. This non-invasive method measures the body's resistance and reactance of the body to the passage of a low-intensity electric current and enables the determination of various body parameters. Bioimpedance provides accurate data on body fat percentage, muscle mass, total body water and other relevant indicators such as phase angle and Z-score. Users will be instructed to remove all metal-containing objects and remain in a supine position on a couch during the measurements, with the legs in 45° abduction, the shoulders in 30° abduction relative to the center of the body and the hands in pronation. After cleaning the skin with alcohol, two adhesive electrodes (Biatrodes Akern Srl, Florence, Italy) will be placed on the surface of the right hand and two on the right foot. The measurement results will be given in different unit measures depending on the specific variable assessed.
Time frame: Visits 1 (Month 1), 2 (Month 2), 3 (Month 3), 4 (Month 7), 5 (Month 19) and 6 (Month 31)
Nutritional assessment
* Mini-Nutritional Assessment (MNA): is a screening tool that helps to identify malnourished older people or those at risk of malnutrition. It assesses 17 items and consists of two main sections, a screening and an overall assessment. The maximum total score is 30 points, with higher scores indicating better nutritional status. * Malnutrition Universal Screening Tool (MUST): a five-step screening tool that assesses three variables (body mass index (BMI), weight loss in 3-6 months and the impact of acute illness) to identify malnourished adults, adults at risk of malnutrition (undernutrition) or obese adults. This tool is recommended by ESPEN for adults in the community, although it is also suitable for nursing home residents and hospital patients and can be used by all health professionals. This screening serves as a predictor of hospital admissions, mortality and associated costs.
Time frame: Visits 1 (Month 1), 2 (Month 2), 3 (Month 3), 4 (Month 7), 5 (Month 19) and 6 (Month 31)
Handgrip strength
Handgrip strength will be assessed using the hand-held Jamar® Plus Smart Dynamometer (Patterson Medical Ltd., Sammons Preston, Nottinghamshire, UK). Manual grip strength will be recorded on both limbs and the dynamometer will be adjusted to hand size prior to testing. The participant's elbow should be in 90° flexion, the forearm is fully supported on a rigid surface (stretcher or table) and the shoulder is in a neutral position. Participants will be instructed to keep the flexion and extension of the wrist neutral. Three measurements will be taken with a one-minute break in between and the best one is used for the analysis. Measurements will be given in kilograms.
Time frame: Visits 1 (Month 1), 2 (Month 2), 3 (Month 3), 4 (Month 7), 5 (Month 19) and 6 (Month 31)
Short Physical Performance Battery (SPPB)
is an instrument to assess the risk of frailty and the risk of falls. This test consists of three tests: a) balance tests; b) 4-meter walking speed; c) five-times stand-up and sit-down test (5STS). In the balance tests, participants will be asked to stand with their feet side by side for 10 seconds, then advance to walk in a half-tandem position for 10 seconds and finally to walk in a tandem position for 10 seconds or longer. For gait speed scoring, participants will be instructed to complete two 4-meter walks at their normal pace, with the faster of the two times being recorded for scoring. For the 5STS, participants are asked to cross their arms over their chest and stand and sit on a chair five times as fast as possible. Each item will be scored on a scale of 0 to 4 points, with a possible total possible score of 12 points, with higher scores indicating better physical performance.
Time frame: Visits 1 (Month 1), 2 (Month 2), 3 (Month 3), 4 (Month 7), 5 (Month 19) and 6 (Month 31)
Frailty phenotype
The Fried frailty phenotype will be used to assess frailty status, which is composed of five main components: i) involuntary weight loss; ii) fatigue or exhaustion; iii) weakness; iv) walking speed; v) physical activity levels. Within this tool and with the intention of assessing physical activity levels, the International Physical Activity Questionnaire (IPAQ) will be used. This questionnaire consists of 7 questions about the frequency, duration and intensity of activity (moderate and intense) performed in the last seven days, as well as walking and sitting time in a working day. This tool allows a standardized and valid measurement of physical activity and is useful in both research and public health. Measurements will be given in a global score (0-5).
Time frame: Visits 1 (Month 1), 2 (Month 2), 3 (Month 3), 4 (Month 7), 5 (Month 19) and 6 (Month 31)
Sarcopenia detection
The risk of sarcopenia will be assessed using the most updated criteria of the European Working Group on Sarcopenia in the Elderly (EWGSOP 2). Following the algorithm proposed by them, the following assessments will be performed: * SARC-F: this five-question questionnaire will be used to identify subjects at risk of sarcopenia. * Manual grip strength: using the protocol previously described. * Five times sit-to-stand test: this is included in the SPPB. * Appendicular muscle mass: will be identified through bioimpedance performed through the protocol described above. * Gait speed. Measurements will be given in a total score and the specific results obtained in each assessment (kilograms for handgrip assessment, time (seconds) for five times sit-to-stand, total appendicular muscle mass; velocity (m/s) for gait speed; and time (seconds) for Timed Up and Go).
Time frame: Visits 1 (Month 1), 2 (Month 2), 3 (Month 3), 4 (Month 7), 5 (Month 19) and 6 (Month 31)
Telephone follow-up
This will be carried out every two weeks during the seven months of the study using a semi-structured interview to record the number of cardiovascular events, hospitalizations and falls of each participant. All measurements will be taken during the monthly evaluations scheduled for the first three months and seven months after the start of the study.
Time frame: Phone calls every two weeks during the seven months of study
Intrinsic capacity - ICOPE Step 1
Screening for loss of intrinsic capacity: Participants will be assessed using the Step 1 basic assessment from the World Health Organization's ICOPE guidelines, a 9-item instrument that is part of the basic assessment. The tool assesses five domains: cognition (2 items), mobility (1 item), vitality (2 items), vision (1 item), and hearing (1 item)-as well as psychological capacity (2 items). The result for each domain is classified as normal or impaired.
Time frame: Visits 1 (Month 1), 2 (Month 2), 3 (Month 3), 4 (Month 7), 5 (Month 19) and 6 (Month 31) For those already in the study this outcome will be assessed only in visits 5 and 6
Plan to share: Undecided
Started May 2025 (actual). Primary completion is estimated for Dec 2028, 43 months after the start.
Of 291 non-industry observational studies under Frailty, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 43 months is above that.
Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 12 and three quarters within 55.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Dec 2026 → Dec 2028 and completion Jan 2027 → Jan 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
European University Miguel de Cervantes